Mark Hill BA (Organisational Management) Executive MBA (IT Management) Age 65 Executive Vice President, Chief Digital Information Officer Mark Hill is the Chief Digital Information Officer at CSL. He leads the enterprise‑wide Digital Technology organisation and its accompanying strategy. Mark plays a key role in how CSL manages plasma donors, connects with patients, virtually collaborates and drives greater efficiencies in operations. He is also driving the modernisation of CSL’s technology landscape to enable long-term growth, resilience and digital innovation. He is a global IT leader with extensive experience in utilising enabling technology to deliver efficiency, productivity, quality and solutions for patients and public health. John Levy* BBus (Fin) Age 65 Senior Vice President Enterprise Accelerator John Levy was appointed as Head of the Enterprise Acceleration Office in March 2025. The Enterprise Acceleration Office will oversee a number of strategic projects across the CSL Group, ensuring successful delivery of its Enterprise change initiatives. Prior to this role John served as Deputy CFO for four years and acted as Interim CFO on several occasions. He has more than 30 years’ experience at CSL in a variety of Finance roles. * John Levy retired from CSL effective 30 June 2025. Ken Lim BCom, LLB (Hons) Age 51 Executive Vice President and Chief Strategy Officer Ken Lim serves as CSL’s Executive Vice President and Chief Strategy Officer. Ken joined CSL in 2013 as Vice President of Strategic Projects where he focused on the Company’s strategy, business development, and mergers & acquisitions. Since then and prior to his current role, he held several positions at CSL Seqirus, including Head of Strategy & Finance and interim General Manager. Prior to joining CSL, Ken advised the Company on a number of strategic initiatives as an investment banker with Merrill Lynch. He started his career as a mergers & acquisitions lawyer at Mallesons Stephen Jaques. Bill Mezzanotte MD, MPH Age 66 Executive Vice President, Head of Research & Development and Chief Medical Officer Bill Mezzanotte, MD was appointed Head of Research and Development in October 2018. He is responsible for developing and executing CSL’s Research & Development strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success. Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas. Mary Oates PhD Analytical Chemistry Age 62 Chief Operating Officer Mary Oates, PhD, was appointed Chief Operating Officer in May 2025. Mary oversees CSL’s enterprise operations organisation, which brings together a range of functions that includes manufacturing, quality, supply chain, technical operations and network strategy. Prior to joining CSL, Mary was the Head of Manufacturing and Supply Vaccines at Sanofi, and prior to Sanofi, Mary held various leadership roles at Pfizer where she oversaw the Innovative Operations and Network Excellence team managing the supply of consumer healthcare and biotechnology products, and spent time leading Global Quality Operations and EHS. Roanne Parry BACP Age 52 Chief Human Resources Officer Roanne Parry was named Chief Human Resources Officer in January 2024. She is responsible for further enhancing CSL’s People strategy as a global employer of choice. Roanne brings more than 25 years of global experience and a broad range of demonstrated leadership and expertise in organizational development; Inclusion and Belonging (I&B) strategies; talent acquisition and management; Total Reward strategies; transformational change and leadership development. 47 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3